UK Markets closed

Biogen Inc. (BIIB.MX)

Mexico - Mexico Delayed price. Currency in MXN
Add to watchlist
0.0000-5,375.0098 (-100.00%)
As of 01:47PM CST. Market open.
Full screen
Previous close5,375.0098
Bid0.0000 x 100
Ask6,229.8701 x 100
Day's range0.0000 - 0.0000
52-week range
Avg. volume50
Market cap0
Beta (5Y monthly)0.17
PE ratio (TTM)0.00
EPS (TTM)390.1680
Earnings date01 Feb 2023 - 06 Feb 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Zacks

    Biogen (BIIB) & Eisai's Lecanemab Secures EMA's MAA Acceptance

    Biogen (BIIB) and Eisai jointly announce that EMA accepts lecanemab's marketing authorization application (MAA) for the treatment of patients with early-stage Alzheimer's disease, for review.

  • Motley Fool

    Is Biogen Stock a Buy Now?

    Moving new medicines to the market can sometimes make biopharmaceutical companies tons of returns. Biogen (NASDAQ: BIIB) just scored a major new drug approval for an Alzheimer's disease therapy, so investors are understandably rushing to evaluate whether to buy the stock. One key factor that could drive Biogen's outperformance in the next few years is the launch of a new neurology medicine.

  • Motley Fool

    Is Biogen Stock a No-Brainer Buy After Eli Lilly's Alzheimer's Disease Setback?

    Lilly's FDA rejection puts Biogen and its partner Eisai in the driver's seat in the Alzheimer's disease drug market.